A study, including one-point-two million people, has revealed that Pfzier/ BioNTech vaccine is ninety-four per cent effective following the second dose. The study, conducted in Israel, used data from Clalit Health Services to assess the effectiveness of the vaccine and matched all individuals who were vaccinated during 20 December 2020 to 1 February 2021 to unvaccinated controls in a one-to-one ratio.
The study highlighted outcomes including COVID-19 related hospitalisation, severe illness and fatalities, symptomatic COVID-19 and infection with severe COVID-19.
“Studies reveal that the Pfzier/ BioNTech vaccine is 94% effective following the second dose.“
Vaccine effectiveness was measured for the study outcomes at days fourteen to twenty after the initial dose of the vaccine, and at one week or more days after the second dose.
Results showed that the vaccine was fifty-seven per cent effective at preventing symptomatic COVID-19 after the first dose, climbing to ninety-four per cent after the second dose. Furthermore, after the second dose, the vaccine was ninety-two per cent effective at preventing severe disease and eighty-seven per cent effective at preventing hospitalisation.
Researchers stated in the New England Journal of Medicine: “This study estimates a high effectiveness of the BNT162b2 vaccine for preventing symptomatic COVID-19 in a noncontrolled setting, similar to the vaccine efficacy reported in the randomised trial. Our study also suggests that effectiveness is high for the more serious outcomes: hospitalisation, severe illness, and death.”See all the latest jobs in Pharmaceutical